Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
LEVODOPA CARBIDOPA
Abbott Products GmbH
20/5 Mg/Ml
Gel
2005-11-18
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 20 mg levodopa and 5 mg carbidopa monohydrate. 100 ml contain 2000 mg levodopa and 500 mg carbidopa monohydrate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Intestinal gel. White to slightly yellow gel. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa administered via a temporary nasoduodenal tube is required before a permanent tube is inserted. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Duodopa is a gel for continuous intestinal administration. For long-term administration, the gel should be administered with a portable pump directly into the duodenum or upper jejunum by a permanent tube _via _percutaneous endoscopic gastrostomy with an outer transabdominal tube and an inner intestinal tube. Alternatively, a radiological gastrojejunostomy may be considered if percutaneous endoscopic gastrostomy is not suitable for any reason. Establishment of the transabdominal port and dose adjustments should be carried out in association with a neurological clinic. A temporary nasoduodenal tube is recommended to find out if the patient responds favourably to this method of treatment and to adjust the dose before treatment with a permanent tube is started. The dose should be adjusted to an optimal clinical response for the individual patient, which means maximizing the functional ON-time during the day by minimizing the number of OFF episodes Read the complete document